Anavex Life Sciences Corp (AVXL)

[kevindenver]

When a company has a suite of biomarkers to integrate into trial designs, it increases the ability of a company and regulators to agree on earlier pivotal phase 2/3 studies.

Pipeline link:

https://www.anavex.com/therapeutic-candidates

Interesting in the 3-71 section that Anavex is looking at P3 trials for the three diseases and no P2's, if I read it correctly. Is the 2-73 analysis being tied in with what is known about 3-71, that the connections allow for Anavex to go directly to P3's for 3-71?

P.S. Not sure if the color shade has any significance, i.e., navy blue (2-73) vs. sky blue (other 3 drugs).